Photo taken from: Yüksel Ürün/X
Apr 2, 2024, 21:45
Yüksel Ürün: KEYNOTE-412 trial shows pembrolizumab + chemoradiotherapy doesn’t significantly improve event-free survival in unselected advanced head and neck squamous cell carcinoma vs placebo
Yüksel Ürün, Medical Oncologist at Ankara University, shared a post on X/Twitter:
“KEYNOTE-412 trial shows pembrolizumab + chemoradiotherapy doesn’t significantly improve event-free survival in unselected advanced head and neck squamous cell carcinoma vs placebo. More targeted approaches needed to enhance outcomes.”
Read further.
Source: Yüksel Ürün/X